Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
0.8425
+0.0025 (+0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
18,558
Open
0.8425
Bid (Size)
0.8540 (1)
Ask (Size)
0.8600 (2)
Prev. Close
0.8400
Today's Range
0.8425 - 0.8425
52wk Range
0.3546 - 4.740
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
March 05, 2025
From
Invivyd
Via
GlobeNewswire
Top movers in Monday's session
February 24, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Performance
YTD
+75.52%
+75.52%
1 Month
-46.34%
-46.34%
3 Month
+44.26%
+44.26%
6 Month
-17.40%
-17.40%
1 Year
-76.73%
-76.73%
More News
Read More
These stocks are moving in today's session
February 24, 2025
Via
Chartmill
(IVVD) - Analyzing Invivyd's Short Interest
February 05, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
February 24, 2025
Via
Chartmill
Wondering what's happening in today's pre-market session?
February 24, 2025
Via
Chartmill
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
February 24, 2025
Via
Benzinga
Exposures
COVID-19
Product Safety
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing
February 24, 2025
From
Invivyd
Via
GlobeNewswire
Top movers in Friday's after hours session
February 21, 2025
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
February 21, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 11, 2025
Via
Benzinga
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
February 10, 2025
From
Invivyd
Via
GlobeNewswire
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
February 10, 2025
Via
Stocktwits
Exposures
Product Safety
Which stocks are experiencing notable movement on Friday?
February 07, 2025
Via
Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look.
February 06, 2025
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 06, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
February 05, 2025
Via
Chartmill
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
February 05, 2025
From
Invivyd
Via
GlobeNewswire
Tuesday's session: most active stocks
February 04, 2025
Via
Chartmill
Unusual volume stocks in Tuesday's session
February 04, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 04, 2025
Via
Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
February 04, 2025
Via
Benzinga
Top movers in Monday's session
February 03, 2025
Via
Chartmill
Discover the most active stocks in Monday's session.
February 03, 2025
Via
Chartmill
Keep an eye on the top gainers and losers in Monday's session.
February 03, 2025
Via
Chartmill
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.